Latest Breaking News On - Ikena oncology - Page 2 : comparemela.com

Wedbush Downgrades Ikena Oncology (NASDAQ:IKNA) to Neutral

Ikena Oncology (NASDAQ:IKNA – Get Free Report) was downgraded by equities researchers at Wedbush from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday, Marketbeat Ratings reports. They currently have a $2.00 target price on the stock, down from their previous target price of $8.00. Wedbush’s […]

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Biohaven (NYSE:BHVN), Genetic Technologies (NASDAQ:GENE)

Wedbush downgrades Ikena, cites discontinuation of lead asset (NASDAQ:IKNA)

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Ikena Oncology (NASDAQ:IKNA) Given "Outperform" Rating at Wedbush

Wedbush reaffirmed their outperform rating on shares of Ikena Oncology (NASDAQ:IKNA – Free Report) in a research note released on Tuesday morning, Benzinga reports. Wedbush currently has a $8.00 price objective on the stock. Wedbush also issued estimates for Ikena Oncology’s Q2 2024 earnings at ($0.26) EPS, Q3 2024 earnings at ($0.28) EPS, Q4 2024 […]